DE60127583D1 - Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid - Google Patents

Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid

Info

Publication number
DE60127583D1
DE60127583D1 DE60127583T DE60127583T DE60127583D1 DE 60127583 D1 DE60127583 D1 DE 60127583D1 DE 60127583 T DE60127583 T DE 60127583T DE 60127583 T DE60127583 T DE 60127583T DE 60127583 D1 DE60127583 D1 DE 60127583D1
Authority
DE
Germany
Prior art keywords
phenyl
oxotetrahydropyran
fluorphenyl
carboxamide
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60127583T
Other languages
English (en)
Other versions
DE60127583T2 (de
Inventor
Donald Eugene Butler
Randall Lee Dejong
Jade Douglas Nelson
Michael Gerard Pamment
Timothy Lee Stuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE60127583D1 publication Critical patent/DE60127583D1/de
Application granted granted Critical
Publication of DE60127583T2 publication Critical patent/DE60127583T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE60127583T 2001-01-09 2001-12-27 Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid Expired - Fee Related DE60127583T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26050501P 2001-01-09 2001-01-09
US260505P 2001-01-09
PCT/IB2001/002729 WO2002055519A2 (en) 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide

Publications (2)

Publication Number Publication Date
DE60127583D1 true DE60127583D1 (de) 2007-05-10
DE60127583T2 DE60127583T2 (de) 2007-12-06

Family

ID=22989433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127583T Expired - Fee Related DE60127583T2 (de) 2001-01-09 2001-12-27 Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid

Country Status (25)

Country Link
US (7) US6476235B2 (de)
EP (1) EP1353917B1 (de)
JP (2) JP4190285B2 (de)
KR (3) KR100677008B1 (de)
CN (4) CN100351252C (de)
AR (1) AR035680A1 (de)
AT (1) ATE358126T1 (de)
BR (1) BR0116739A (de)
CA (1) CA2432064C (de)
CY (1) CY1106590T1 (de)
CZ (1) CZ20031893A3 (de)
DE (1) DE60127583T2 (de)
DK (1) DK1353917T3 (de)
ES (1) ES2282200T3 (de)
HK (2) HK1060572A1 (de)
HU (1) HUP0302647A3 (de)
IL (4) IL156461A0 (de)
MX (1) MXPA03005284A (de)
PL (1) PL365283A1 (de)
PT (1) PT1353917E (de)
RU (1) RU2244714C1 (de)
TW (1) TWI293073B (de)
WO (1) WO2002055519A2 (de)
YU (1) YU49003A (de)
ZA (1) ZA200304684B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
US7199261B2 (en) * 2001-07-06 2007-04-03 Teva Pharmaceutical Industries Ltd Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ATE368661T1 (de) * 2002-08-06 2007-08-15 Warner Lambert Co Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
KR100765555B1 (ko) * 2002-08-06 2007-10-09 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2ｒ,4ｒ)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1ｈ-피롤-3-카르복실산 페닐아미드의 제조 방법
AU2003295684A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
CN1774421A (zh) * 2003-04-14 2006-05-17 沃尼尔·朗伯有限责任公司 制备5－(4－氟苯基)－1－[2－((2r,4r)－4－羟基－6－氧代－四氢－吡喃－2－基)乙基]－2－异丙基－4－苯基－1h－吡咯－3－羧酸苯基酰胺的方法
US7166638B2 (en) 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
EP1636243B1 (de) * 2003-06-13 2013-11-06 Boehringer Ingelheim International GmbH Chirale liganden zur anwendung in asymmetrischen synthesen
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
JP4638441B2 (ja) 2003-10-24 2011-02-23 ロンザ アーゲー ６，６，６−トリハロ−３，５−ジオキソヘキサン酸エステルの生産方法
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
AU2005232959A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CZ299175B6 (cs) * 2004-06-17 2008-05-07 Zentiva, A. S Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí
MX2007000582A (es) * 2004-07-16 2007-03-30 Lek Pharmaceuticals Productos de degradacion oxidativa de atorvastatin calcio.
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
RU2470916C2 (ru) * 2004-07-30 2012-12-27 Экселиксис, Инк. Производные пиррола как лекарственные вещества
CA2585836A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
WO2006097909A1 (en) * 2005-03-14 2006-09-21 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1705175A1 (de) * 2005-03-24 2006-09-27 ratiopharm GmbH Verfahren zur Herstellung von C5-Produkten und ihre Verwendung in der Synthese von Atorvastatin
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
DE602006014193D1 (de) 2005-11-21 2010-06-17 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
CA2652412A1 (en) * 2006-05-15 2007-11-22 Ratiopharm Gmbh Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives
KR101069698B1 (ko) * 2008-08-28 2011-10-04 한국화학연구원 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2327682A1 (de) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte.
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
KR100986755B1 (ko) * 2009-12-29 2010-10-08 김우진 노즐 회전장치 및 이를 갖는 분수
CN101892276B (zh) * 2010-06-12 2012-11-21 郝志艳 一种阿托伐他汀钙化合物及其新方法
MX2013002809A (es) 2010-09-16 2013-04-29 Dsm Sinochem Pharm Nl Bv Esteres de acidos hexanoicos.
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
EA201891817A1 (ru) * 2016-02-11 2019-07-31 Стихтинг Катхолике Юниверситейт Новый класс соединений для лечения сердечно-сосудистых заболеваний
US10699269B1 (en) * 2019-05-24 2020-06-30 Blockstack Pbc System and method for smart contract publishing
US11513815B1 (en) 2019-05-24 2022-11-29 Hiro Systems Pbc Defining data storage within smart contracts
US11657391B1 (en) 2019-05-24 2023-05-23 Hiro Systems Pbc System and method for invoking smart contracts
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CZ294695B6 (cs) 1995-07-17 2005-02-16 Warner-Lambert Company Krystalická forma II atorvastatinu nebo jeho hydrátu, farmaceutický přípravek obsahující tuto krystalickou formu II atorvastatinu a její použití v lékařství
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6297274B1 (en) * 1996-04-10 2001-10-02 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IL127058A (en) 1996-07-29 2001-07-24 Warner Lambert Co Process for the synthesis of protected esters of acid (S) - 4,3 dehydroxybutyric
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
US6476235B2 (en) 2002-11-05
JP2008100989A (ja) 2008-05-01
ATE358126T1 (de) 2007-04-15
KR20060015698A (ko) 2006-02-17
IL189357A0 (en) 2008-06-05
US7361771B2 (en) 2008-04-22
US20070032662A1 (en) 2007-02-08
AR035680A1 (es) 2004-06-23
CN100351252C (zh) 2007-11-28
CN101024626A (zh) 2007-08-29
RU2244714C1 (ru) 2005-01-20
CZ20031893A3 (cs) 2004-03-17
HK1060572A1 (en) 2004-08-13
MXPA03005284A (es) 2003-09-25
JP2004520351A (ja) 2004-07-08
DK1353917T3 (da) 2007-06-18
HUP0302647A2 (hu) 2003-11-28
KR20060114395A (ko) 2006-11-06
US7183408B2 (en) 2007-02-27
BR0116739A (pt) 2003-09-30
CN1696129A (zh) 2005-11-16
US20070032664A1 (en) 2007-02-08
KR20030065594A (ko) 2003-08-06
IL189359A0 (en) 2008-06-05
KR100833911B1 (ko) 2008-06-03
US20070032663A1 (en) 2007-02-08
PL365283A1 (en) 2004-12-27
HUP0302647A3 (en) 2009-03-30
US7399773B2 (en) 2008-07-15
US20050239869A1 (en) 2005-10-27
US6545153B1 (en) 2003-04-08
CN1489587A (zh) 2004-04-14
ES2282200T3 (es) 2007-10-16
CY1106590T1 (el) 2012-01-25
US6933393B2 (en) 2005-08-23
CN1222521C (zh) 2005-10-12
WO2002055519A3 (en) 2002-09-19
US20020133026A1 (en) 2002-09-19
IL156461A0 (en) 2004-01-04
JP4190285B2 (ja) 2008-12-03
US7371855B2 (en) 2008-05-13
ZA200304684B (en) 2004-06-28
KR100677008B1 (ko) 2007-02-01
DE60127583T2 (de) 2007-12-06
IL189358A0 (en) 2008-06-05
EP1353917B1 (de) 2007-03-28
YU49003A (sh) 2006-05-25
CN1907984A (zh) 2007-02-07
AU2002222430B2 (en) 2007-05-17
HK1084114A1 (en) 2006-07-21
CA2432064A1 (en) 2002-07-18
WO2002055519A2 (en) 2002-07-18
EP1353917A2 (de) 2003-10-22
PT1353917E (pt) 2007-05-31
US20030195353A1 (en) 2003-10-16
CA2432064C (en) 2007-09-11
TWI293073B (en) 2008-02-01
KR100582326B1 (ko) 2006-05-22

Similar Documents

Publication Publication Date Title
DE60127583D1 (de) Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid
ATE298326T1 (de) Verfahren zur epoxidierung von olefinen
ATE353322T1 (de) Verfahren zur herstellung von 2- (chinoxalin-5- ylsulfonylamino) -benzamid-verbindungen
ATE437486T1 (de) Verfahren zur konfiguration von physischen kanälen
ATE487709T1 (de) Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)benzolamin
DE60327356D1 (de) Verfahren zur synthese von metallnanoteilchen
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
DE602004013990D1 (de) Ernen von spänen
DE602004012925D1 (de) Protokoll zur Erbringung von Diensten
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DE60321098D1 (de) Verfahren zur Herstellung von Hydroxyalkyl(meth)acrylat
DE60113157T2 (de) Verbessertes verfahren zur herstellung von simvastatin
DE60315308D1 (de) VERFAHREN ZUR HERSTELLUNG VON 5-(4-FLUORPHENYL)-1-i2-((2R,4R)-4-HYDROXY-6-OXOTETRAHYDROPYRAN-2-YL)ETHYLö-2-ISOPROPYL-4-PHENYL-1H-PYRROL-3-CARBONSÄUREPHENYLAMID
DE60219746D1 (de) Verfahren zur Herstellung von Biarylverbindungen
DE60325140D1 (de) Verfahren zur Herstellung von Hydroxyalkyl(meth)acrylat
DE60225721D1 (de) Verfahren zur zugriffskontrolle über spezifischen dienste via einem verteiler
ATE305939T1 (de) Verfahren zur synthese von (2s,3as,7as)-1-((s)-
ATE306485T1 (de) Verfahren zur herstellung von 2-(-5-(4- fluorphenyl)-3-pyridylmethylaminomethyl)-chroma
DE60117687D1 (de) Verfahren zur synthese von pfropfpolymeren
BRPI0409333A (pt) processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen
ATE280775T1 (de) Verfahren zur synthese von (2s,3as,7as)-1-((s)-
ATE382035T1 (de) Verfahren zur herstellung von n-substituierten phthalimiden
DE50307097D1 (de) Katalytisches verfahren zur herstellung von carbonyl-verbindungen
DE10295581D2 (de) Verfahren zur Synthese von All-D-Peptiden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT

8339 Ceased/non-payment of the annual fee